Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison.
J Comp Eff Res
; 9(3): 191-199, 2020 02.
Article
em En
| MEDLINE
| ID: mdl-31916448
ABSTRACT
Aim:
To compare the overall survival of patients with metastatic urothelial carcinoma (mUC) who failed platinum-based chemotherapy and received durvalumab or chemotherapy. Patients &methods:
In an indirect comparison of patients with mUC who failed platinum-based chemotherapy, those who received durvalumab in a single-arm study were matched to patients from the Flatiron oncology electronic medical record database who received chemotherapy (n = 158 for each cohort). Matching was based on propensity scores. Kaplan-Meier methods and Cox regression models were utilized.Results:
Median overall survival was 11.2 months (95% CI 7.2-16.9) for durvalumab versus 8.2 months (95% CI 6.7-9.8) for chemotherapy (hazard ratio 0.63; 95% CI 0.48-0.84).Conclusion:
As a second-line therapy for mUC, durvalumab was associated with longer overall survival than chemotherapy.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Urológicas
/
Anticorpos Monoclonais
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article